DAXOR CORP (DXR) - 10-K Summary for Fiscal Year Ended December 31, 2009
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2009. Daxor Corporation is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and Volumex diagnostic kits, alongside biotechnology services provided by its subsidiary, Scientific Medical Systems (cryobanking of blood and semen). The company operates as a "smaller reporting company" and is listed on the NYSE Amex.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Operating Revenues | $1,688,826 | $1,761,055 |
| Loss from Operations | $(5,109,188) | $(5,207,152) |
| Net Income | $5,822,758 | $15,123,269 |
| Investment Income (Net) | $12,261,060 | $24,888,385 |
| Cash and Cash Equivalents | $277,088 | $2,545,040 |
| Total Assets | $75,186,990 | $76,824,181 |
| Total Liabilities | $27,561,653 | $33,363,540 |
| Stockholders' Equity | $47,625,337 | $43,460,641 |
| Dividends Paid Per Share | $1.35 | $1.50 |
Note: Net income is driven almost entirely by investment activities (dividends and realized gains on securities), which offset significant operating losses.
Material Changes vs. Prior Period
- Operating Revenue: Decreased 4.1% to $1.69 million. Equipment sales dropped significantly (1 unit sold in 2009 vs. 4 in 2008), while kit sales volume increased 14.5% due to higher utilization of existing instruments.
- Operating Loss: Narrowed slightly to $5.11 million from $5.21 million, primarily due to a $211,450 reduction in payroll expenses.
- Investment Performance: Net realized gains on securities fell 43.8% to $9.69 million. This decrease was due to strategic sales of Dynegy, USEC, and Bank of America shares to generate tax savings and lower cost basis, despite a 17% increase in dividend income.
- Liquidity: Cash and cash equivalents declined by approximately $2.27 million, primarily used to fund the operating loss and repay margin loans.
Guidance, Outlook, Risks, and Contingencies
- Market Adoption Challenges: Management notes that despite clinical evidence supporting the BVA-100, administrative acceptance at hospitals remains difficult due to cost-effectiveness concerns and reimbursement policies.
- Reimbursement Risk: A 2008 CMS policy change reduced reimbursement for diagnostic radiopharmaceuticals by approximately 33%, requiring hospitals to absorb the cost of the Volumex kit. This remains a significant headwind.
- Investment Dependency: The company relies heavily on its investment portfolio to fund operations. Cumulative operating losses over the last five years were $26.1 million, offset by $62.7 million in investment income. Management warns that future investment income is not guaranteed.
- SEC Wells Notices: The company and its CEO received Wells Notices in 2005, 2007, and November 2009 regarding potential violations of the Investment Company Act (operating as an unregistered investment company). No closing notices have been received, but the risk of designation remains.
- Patent Expiration: Patents for the BVA-100 expire in May 2010. The company is developing a next-generation system to measure total body albumin to secure new patent protection.
- Customer Concentration: Four hospitals accounted for 60.3% of Blood Volume Kit sales in 2009.
Key Facts for Investor Verification
- Operating Viability: Verify the sustainability of the business model given that core operations (medical devices and cryobanking) generated a loss of $5.1 million, entirely subsidized by investment gains.
- Investment Portfolio Risk: Assess the concentration risk in the investment portfolio (93.5% in utility stocks) and the impact of rising interest rates on portfolio value and dividend yields.
- Regulatory Status: Monitor the status of the SEC Wells Notices regarding the Investment Company Act classification.
- Patent Timeline: Confirm the progress of the new patent application for the albumin measurement system before the May 2010 expiration of current BVA-100 patents.
- Reimbursement Policy: Track any changes in CMS or private insurer reimbursement policies for blood volume analysis, which currently face a 33% reduction in coverage.